Investor Relations

Mr. Deng Ning, partner of Dingxin Capital, said: "Dingxin Capital has been focusing on 'major unmet clinical needs' and continuously supporting independent and innovative platform-based medical companies. Radiation rectal injury is the main complication after pelvic tumor radiotherapy, which seriously affects the quality of life of patients and there was no effective solution before. Radiotherapy protective hydrogel provides a new solution for the prevention of radiation rectal injury and has huge market potential. Reunion's global use of cervical cancer radiotherapy protective isolation hydrogel fills the gap in the field of radiotherapy protective hydrogel in China. We are very pleased to lead the investment in Reunion and are optimistic about the company's biomaterial platform technology accumulated over many years and the clear goal planning and strong execution of the founding team. We look forward to Reunion's products being launched on the market as soon as possible to benefit the majority of patients." Mr. Mao.

Mr. Mao Shuo, Executive Director of Qiming Venture Partners, said: "Reunion has taken a different approach to develop a globally innovative PEG hydrogel platform, and has developed a number of innovative Class III medical devices based on this technology platform, which has extended a rich product pipeline. The company's team has strong execution capabilities, has completed various milestone plans, and is committed to promoting the application of innovative biomaterial technologies in clinical and medical fields. We I am very optimistic about the development prospects of biomedical materials and I am very happy to work with the company team to promote the development of the industry. "

Guoxin Innovation Equity said: "As a cutting-edge biomedical material platform enterprise, Reunion has a core team that has been deeply involved in the field of medical hydrogels for many years. It has independent core technologies, effective execution, and its products are highly innovative and leading the world. China's biomaterials industry is a blue ocean field with huge potential. We expect Reunion to make its own contribution to the development of China's biomaterials. We are full of confidence in the company's future development. We will also continue to empower outstanding companies such as Reunion to fill clinical needs and benefit the patient population."

Ms. Jiang Jiajia, Managing Director of China Renaissance Capital's Medical and Life Science Division, said: "As a leader in China's medical hydrogels and biomaterials, Reunion has built a differentiated innovative material platform and continuously develops innovative device products for intractable cancers in China and the world to solve currently unmet clinical needs. As a partner of Reunion, China Renaissance Capital is fortunate to participate in the milestones of the company's development and will continue to help the company achieve great results. "